Filing Flows › IGC Pharma (IGC) › Stock forecast & fair value
IGC Pharma (IGC) stock forecast and price target
IGC Pharma (IGC) trades at $0.20. One analyst's price target is $6.00 (30×).
IGC Pharma's latest quarter
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IGC stock?
One analyst's 12-month target is $6.00, 30× from $0.20. The average rating is none.
Does IGC Pharma usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is IGC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.